We examined metabolic profiles and cardiovascular-renal outcomes in a prospective cohort of Chinese patients with young-onset diabetes defined by diagnosis age ,40 years. Patients with type 1 diabetes and normal-weight (BMI ,23 kg/m 2 ) and overweight (BMI ‡23 kg/m 2 ) patients with type 2 diabetes were compared.
Amid the current diabetes pandemic, the perpetual decline in the age of disease onset is a disturbing worldwide trend that has major public health ramifications (1) . In susceptible ethnic groups including Asians, type 2 diabetes has emerged as the predominant form of dysglycemia in childhood and adolescence (2) (3) (4) (5) . The evolving epidemic of obesity in youth as a result of global industrialization favoring energy conservation over energy expenditure is the main culprit for the increasingly younger age of diabetes development. Consistent with the role of insulin resistance in type 2 diabetes, development of cardiometabolic risk factors precedes the diagnosis of diabetes in a large proportion of patients (3, 4) .
Relative to adult-onset diabetes, early development of disease imposes a longer exposure to the hazards of chronic hyperglycemia and increases the likelihood of progression to overt complications even before reaching middle age. In Pima Indians, the incidence of diabetic nephropathy was similar between patients with youngand adult-onset type 2 diabetes and at any given age, and the cumulative incidence of nephropathy was higher in those with young-onset disease (5) . Furthermore, compared with agematched members of the general population, young individuals with early diabetes have 30 times the risk of stroke and 14 times the risk of myocardial infraction, reinforcing the notion that young diabetic patients are not impervious to the life-threatening manifestations of atherosclerosis (6) . While overwhelming evidences support the efficacy of global risk factor control on cardiovascular-renal protection among older patients with or without established comorbidities (7) , data on the benefit of aggressive intervention with early use of adjunctive therapy such as statins and renin-angiotensin system blockade in younger patients are limited.
On a separate note, it has long been recognized that a proportion of Asian patients with type 2 diabetes have a low BMI, which deviates from their obese counterparts in terms of metabolic profile and early requirement for insulin (8) . In a previous report, we have remarked on the heterogeneity of diabetic phenotypes in Chinese and showed the correlation of low BMI with insulin deficiency as measured using C-peptide (9) . In another study of young lean Asian diabetic patients with detailed assessment of insulin sensitivity using hyperinsulinemic-euglycemic clamp, patients with type 2 diabetes were more insulin resistant than those with type 1 diabetes despite comparable anthropometric indices (10 A trained team of personnel in the HA routinely coded all hospital discharge diagnoses according to the ICD-9. Coronary heart disease was defined as myocardial infarction (ICD-9 code 410), ischemic heart disease (ICD-9 code 411-414), or death owing to coronary heart disease (ICD-9 code 410-414).
Congestive heart failure was defined as nonfatal or fatal heart failure (ICD-9 code 428). Presence of family history was observed more frequently in patients with type 2 than type 1 diabetes. Anti-GAD was detected in 31.0% of patients with type 1 diabetes, 11.8% of normal-weight patients with type 2 diabetes and 2.9% of overweight patients with type 2 diabetes (P , 0.001).
Compared with patients with type 1 diabetes, those with type 2 diabetes, either normal-or overweight, had higher rates of micro-/macroalbuminuria, retinopathy and peripheral sensory neuropathy. Background frequencies of CVDs were overall low in this young cohort, and between-group comparison of rates of past macrovascular events did not reach statistical significance.
Over a median follow-up duration of 9.3 years (interquartile range 6.2-11.6), 138 patients (type 1 diabetes, n = 1; normalweight type 2 diabetes, n = 26, and overweight type 2 diabetes, n = 111) developed CVD, while 141 patients (type 1 diabetes, n = 4; normal-weight type 2 diabetes, n = 34; and overweight type 2 diabetes, n = 103) developed ESRD. The Kaplan-Meier curves for the cumulative incidences of major clinical outcomes are shown in Fig. 1A and B. The incidence of CVD was highest in the overweight type 2 diabetic group and lowest in type 1 diabetes, with respective rates of 9.6 (95% CI 8.0-11.6), 5.1 (95% CI 3.5-7.5), and 0.6 (95% CI 0.1-3.2) per 1,000 person-years in overweight type 2 diabetes, normalweight type 2 diabetes, and type 1 diabetes (P , 0.01 for all comparisons). A similar trend was observed in the incidences of ESRD, and the corresponding rates for overweight type 2 diabetes, normal-weight type 2 diabetes, and type 1 diabetes were 8.4 (95% CI 6.9-10.2), 6.4 (95% CI 4.6-9.0), 
Heterogeneity of Type 2 Diabetes in Asia
Asian patients with type 2 diabetes represent a heterogeneous group in terms of age of onset, mode of presentation, metabolic phenotype, and insulin requirement. It is long recognized that a large proportion of Asian patients with type 2 diabetes are of normal body weight. In the current study, 40% of type 2 diabetic patients had normal weight. This is consistent with findings from the recent AsDiab study, which showed that up to 40% had BMI ,23 kg/m 2 (4). In the current study, among the subset of patients with measurements of autoimmune antibodies, only 11.8% of the lean patients and 2.9% of the overweight ones with type 2 diabetes had anti-GAD, compared with 31% of patients with type 1 diabetes. On the other hand, it is quite clear that lean patients with type 2 diabetes have lower b-cell reserve with earlier insulin requirement compared with obese patients (9) . We speculate that lean Chinese patients have a constitutional predisposition to b-cell dysfunction and that genetic factors rather than autoimmunity are involved in the pathogenesis of diabetes (8) . In support of this, a significantly greater proportion of normal-weight type 2 (54.1%) compared with type 1 diabetic (22.0%) patients have a positive family history. Furthermore, recent genomewide association studies have revealed that the majority of loci associated with type 2 diabetes are implicated in b-cell structure and biology (24) .
Despite lower BMI, other metabolic indices of blood pressure and lipids were worse in the lean type 2 diabetic group compared with patients with type 1 diabetes. The incidences of CVD and ESRD were also higher among normalweight type 2 diabetic patients, although there was no statistically significant increase in hazards of lean type 2 relative to type 1 diabetes for cardiovascular-renal outcomes when adjusted for age, sex, and time from diagnosis. The significant age disparity between the two groups may partly account for differences in baseline risk profile and complication rates. Underlying insulin resistance in type 2 diabetes, even in normal-weight patients, may also contribute to development of cardiometabolic risk factors. Herein, Hsu et al. (10) have demonstrated lower insulin sensitivity in lean patients with type 2 diabetes compared with type 1 diabetes, suggesting that insulin resistance is not exclusive to those who are obese.
Metabolic Control
In this cohort of patients with type 2 diabetes, 54.3% had hypertension and 73.9% had dyslipidemia. Our results agree with the SEARCH for Diabetes in Youth Study reporting obesity in 80%, hypertension in one-quarter, and elevated LDL cholesterol in one-half of young affected people in the U.S. (25) . The early development of cardiometabolic risk factors is further highlighted in the recently published TODAY (Treat Type 2 Diabetes Early and Aggressively in Young) trial of adolescents with newly diagnosed type 2 diabetes (26, 27) . Despite the provision of intensive monitoring, lifestyle reinforcement, and medical support in a trial setting, the frequency of hypertension was increased threefold from 11.6 to 33.8% while the frequency of high-risk LDL cholesterol was increased twofold from 4.5 to 10.7% over an average follow-up time of 4 years. Importantly, among youth who were prescribed statins, only one-third achieved the prespecified LDL cholesterol goal. We observed gross underuse of lipid-lowering and antihypertensive drugs despite high prevalence of atherogenic risk factors. Likewise, the number of patients using renin-angiotensin system blockade fell short of the proportion with clinical nephropathy. A substantial percentage of our patients were not achieving international targets for blood pressures and lipids. Based on a longitudinal evaluation of care provision in the diabetic population in the U.S. (28) , not only were young patients less able to reach treatment targets compared with older adults but the rates of target attainment in the young group have not changed over the past decade. The lack of evidence-based guideline on optimal risk factor management in young disease population and concerns over possible adverse effects are major reasons for clinical inertia and delay in initiation of high-impact therapy such as statins. It is also well recognized that young people with diabetes are more difficult to manage owing to greater level of diabetes-related distress, competing social demands, poor drug adherence, and high default rates.
Limitations
Our study has the following limitations. First, although we have set criteria for defining type 1 diabetes, it remains possible that some patients with type 2 diabetes were misclassified as type 1, given increasing recognition of overlap in clinical presentation of the two types. Recently, the SEARCH study group proposed an aetiological approach in characterizing diabetes among young people, using autoimmunity and insulin sensitivity as the two factors considered (29) . However, in view of the low frequency of autoimmune positivity in Asians, we believe that this scheme may not be applicable to our population. It is also possible that a very small proportion of the normal-weight group had mature-onset diabetes of the young. We have previously reported mutations in the glucokinase and hepatocyte nuclear factor 1-a genes in 3 and 5%, respectively, of Chinese diabetic patients with a positive family history (30) . Second, as we have only used health records from public hospitals to identify cardiovascular and renal end points, events that were treated in the private sector were not captured. Based on government statistics, we estimated that this would be ,15% of total hospitalization during follow-up, as there is a huge discrepancy in costs between private and public services, but this incomplete capture pertains to all three groups of patients examined. Third, the small number of events in our cohort, particularly in the type 1 diabetic group, limits interpretation of results from the Cox model, as evidenced by the wide CI. Lastly, we have studied only Chinese patients, and our results may not be generalizable to other Asian ethnic groups.
Conclusion
We have shown that among Chinese patients with young-onset diabetes, those with type 2 diabetes had higher rates of CVD and ESRD compared with type 1 diabetes. The increased risks of cardiovascular-renal complications in type 2 diabetes were attributable to attendant metabolic abnormalities of obesity, hypertension, and dyslipidemia. The high cardiometabolic burden notwithstanding, there was suboptimal provision of important ancillary treatment of these conditions, with underachievement of metabolic targets. Our results draw attention to existing shortfalls in effective reach and management of this challenging patient population and support the need for further studies to evaluate the longterm benefit of aggressive risk factor control in young individuals.
